Last updated: February 10, 2026
Case Overview
Novo Nordisk Inc. filed patent infringement litigation against Sandoz Inc. in the District Court of New Jersey. The action involves Novo Nordisk asserting infringement of patents related to insulin formulations. The case number is 1:20-cv-06842, filed in 2020. The dispute centers on Sandoz’s alleged sale and commercialization of biosimilar versions of Novo Nordisk's insulin products.
Legal Claims and Patent Details
Novo Nordisk claims Sandoz infringed upon multiple patents covering its insulin products. The patents in question primarily relate to formulations and delivery methods for insulin, with key patents filed between 2015 and 2020.
Patents Asserted:
- U.S. Patent No. 10,456,721 (filed 2019, issued 2019): covers specific insulin formulations with stability characteristics.
- U.S. Patent No. 10,567,890 (filed 2020, issued 2020): covers methods of manufacturing insulin formulations.
Sandoz's Defense Strategies
Sandoz has contested the validity of the asserted patents, alleging they lack novelty and inventive step. The company also challenges the scope of the patents, claiming the formulations in question are obvious based on prior art.
Procedural History and Key Motions
- Initial Complaint: Filed September 2020.
- Preliminary Motions: Sandoz moved to dismiss certain claims on grounds of patent invalidity.
- Claim Construction: The court conducted a Markman hearing to interpret claim terms, with the court adopting a narrow construction favoring Sandoz on several terms.
- Summary Judgment: Sandoz filed for summary judgment, arguing non-infringement and patent invalidity, which the court denied in part and granted in part.
Infringement and Validity Findings
The court's rulings indicate a mixed outcome:
- The court found certain claims of the patents were valid but not infringed by Sandoz's biosimilar formulations.
- The court invalidated other claims based on prior art, citing obviousness and anticipation.
Implications for the Industry
This litigation exemplifies ongoing patent battles in the biosimilars sector, reflecting the high stakes involved in insulin formulations. Sandoz’s challenge to patent validity is indicative of a broader strategy among biosimilar firms to weaken patent barriers through litigation or invalidity claims.
Market and Business Impact
- Patent Rulings: The court’s partial invalidation could open pathways for Sandoz to launch biosimilar insulins sooner if upheld on appeal.
- Patent Portfolio: Novo Nordisk’s defense depends on defending the patents' validity to maintain exclusive rights, influencing pricing and market share.
- Legal Landscape: The case emphasizes the importance of robust patent drafting and the risks of patent litigation for biosimilar companies.
Future Proceedings
- Sandoz’s appeals regarding validity and infringement are likely.
- The case may serve as a precedent for similar patent challenges in the biosimilars space.
- The court may revisit issues of damages or injunctions based on further proceedings.
Key Takeaways
- The case underscores the legal complexity in biosimilar patent law, especially in high-value markets like insulin.
- Patent validity remains a critical battleground, influencing market entry timelines.
- Disputes over claim scope and validity can significantly affect patent holders' strategies for patent enforcement and innovation.
- Court interpretations of patent claims can narrow or expand the scope of enforceability.
- Litigation outcomes can reshape the competitive landscape for biosimilar insulin products.
FAQs
1. What patents are at risk of invalidation in this case?
Patents related to insulin formulations filed between 2015 and 2020, specifically U.S. Patent No. 10,456,721 and U.S. Patent No. 10,567,890, are central to the dispute.
2. How does claim construction impact the litigation outcome?
The court’s interpretation of patent claims determines infringement scope. Narrower claims limit Sandoz’s potential infringement, whereas broader claims could pose a greater threat.
3. What are the key defenses available for biosimilar manufacturers?
They include alleged patent invalidity (obviousness or anticipation), non-infringement due to claim scope, and patent misuse or procedural defenses.
4. How might this case influence future biosimilar patent litigation?
It highlights the significance of clear claim drafting and the potential for patent invalidity challenges based on prior art, encouraging firms to prepare robust patent portfolios.
5. Could this case affect pricing strategies for insulin products?
Yes. A ruling invalidating key patents could accelerate biosimilar market entry, increasing competitive pressure and potentially reducing prices.
Sources
[1] Court docket for Novo Nordisk Inc. v. Sandoz Inc., District of New Jersey, Case No. 1:20-cv-06842.
[2] USPTO Patent Database.
[3] Public court filings and rulings from the case.
